

ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2012 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 18, 2012-- [ImmunoGen, Inc.](#) (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, January 27, 2012, to discuss ImmunoGen's financial results for the three-month period ended December 31, 2011 – the second quarter of the Company's 2012 fiscal year. Management also will provide an update on the Company.

To access the live call by phone, dial 913-312-1231. Passcode: 5537853. The call also may be accessed through the Investor Information section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through February 3, 2012.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

Source: ImmunoGen, Inc.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com

or

For Media:
The Yates Network
Barbara Yates, 781-258-6153